Knopp Biosciences LLC is a privately held company managing a portfolio of future milestone payments and product royalties. Founded in 2004, the company sold and/or spun off its two drug pipelines in 2022. Knopp’s clinical stage Kv7 platform, small-molecule treatments for epilepsy and other hyperexcitability disorders, was acquired by Biohaven Pharmaceuticals and is currently in late stage clinical trials (www.biohavenpharma.com). Knopp’s clinical stage dexpramipexole platform (“Dex”) was spun off to Areteia Therapeutics Inc. Dex failed in Phase III studies and Areteia ceased operations in November 2025. Knopp members are invited to login to the investor portal to view the company’s latest newsletters, financial statements, and other proprietary information. All other inquiries should be directed to info@knoppbio.com. For immediate inquiries, e-mail investor relations E-Mail Knopp © Copyright 2026 Knopp Biosciences LLC. All Rights Reserved
